BlueRun Ventures Hosts Dialogue with BioMap and VoxelX on the Paradigm Shift of AI in Drug Discovery

AI and computing are playing an increasingly irreplaceable role in the drug development process, offering breakthroughs for pipeline candidates that are difficult to develop into drugs using traditional methods. Each pipeline corresponds to a specific drug and, by extension, a class of diseases, with clearly defined implementation scenarios and application prospects.

Major traditional pharmaceutical companies are continuously expanding their presence, and the AI drug discovery sector on Nasdaq has seen the listing of companies such as Schrödinger, Relay Therapeutics, Recursion Pharmaceuticals, AbCellera, and Exscientia. Meanwhile, the development of AI-driven drug discovery in China is also gaining significant momentum, with a wave of innovative companies emerging at the intersection of artificial intelligence and pharmaceuticals.

Although AI and computational methods can accelerate the efficiency of new drug research, the pharmaceutical industry remains characterized by high technical barriers and lengthy development cycles. To date, no AI-developed drug has achieved a true therapeutic milestone.

On the one hand, AI-driven drug discovery represents an irreversible transformation, with numerous opportunities awaiting exploration; on the other hand, this exciting industry is still in its early stages, and the path forward remains to be charted.

On Saturday, April 23, from 10:00 to 12:00, BlueRun Ventures will host an online bio-themed salon titled “The Paradigm Revolution of AI and Computing in Drug Discovery.” During the event, BlueRun Ventures will engage in dialogue with BioMap and Xili Technology to discuss the challenges and opportunities in AI-driven drug discovery.

This event will be held via Tencent Meeting. Entrepreneurs, industry professionals, academic experts, and investors are welcome to scan the QR code to join! To facilitate thorough online interaction, this event will operate on a pre-registration basis. Please scan the QR code to access the registration link, where you can submit topics of interest or questions you would like to discuss with our guest speakers. These will be addressed during the event.

See you online!

BlueRun Ventures was established in Silicon Valley, USA, in 1998. BlueRun Ventures China was founded in 2005 and is one of the largest early-stage investment funds in China. The firm manages multiple dual-currency funds in both USD and RMB, with assets under management exceeding RMB 10 billion. Its investment focus centers on Pre-A and Series A rounds. To date, it has invested in more than 150 startups and has been ranked first in Zero2IPO’s “Top 30 Early-Stage Investment Institutions in China” as well as first in CVSource’s “Top 30 Best Early-Stage Venture Capital Firms in China.” BlueRun Ventures continues to prioritize foundational sciences and cutting-edge technologies, having built a portfolio in biotechnology that includes multiple “new species” companies such as BioMap and Beiheng Biopharma.